Every Biosimilar Should Have Its Own Medicare Pay Code, CMS Told
This article was originally published in The Pink Sheet Daily
Sandoz and other biosimilar stakeholders react at a public meeting to indications that CMS might be planning to put multiple biosimilars into a single Medicare billing code, meaning they would all be reimbursed at the same amount, when they reference the same innovator product.
You may also be interested in...
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.
Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.